ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Professional Societies: Tobacco Industry Should Pay For Research, AACR Says

August 15, 1997

Freireich Blasts Prevention Advocates, Defends Treatment

September 15, 1978

The Cloning Story: How Dolly Made Page 1 And A Physicist Got Air Time

May 15, 1998

NCAB Committee Approves Staff Plan For New Comprehensive Cancer Center Grant Mechanism

April 29, 1988

Firm’s Information System Embedded In iKnowMed For Treatment Outcomes.

June 29, 2001

Did The Dog Eat It? NIH Fails To Turn In A Prostate Cancer Plan Assigned By Senate

April 23, 1999